RUBRACA
Total Payments
$4.8M
Transactions
2,019
Doctors
38
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $2.2M | 297 | 1 |
| 2019 | $132,938 | 250 | 36 |
| 2018 | $644,871 | 514 | 0 |
| 2017 | $1.9M | 958 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.7M | 1,769 | 97.3% |
| Consulting Fee | $103,000 | 54 | 2.1% |
| Travel and Lodging | $25,633 | 105 | 0.5% |
| Food and Beverage | $4,305 | 91 | 0.1% |
Payments by Type
Research
$4.7M
1,769 transactions
General
$132,938
250 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3) | Clovis Oncology, Inc. | $808,069 | 0 |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3) | Clovis Oncology, Inc. | $805,179 | 1 |
| A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR) | Clovis Oncology, Inc. | $768,206 | 0 |
| A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2) | Clovis Oncology, Inc. | $697,471 | 0 |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) (ARIEL2) | Clovis Oncology, Inc. | $371,195 | 1 |
| A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3) | Clovis Oncology, Inc. | $367,956 | 0 |
| A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) | Clovis Oncology, Inc. | $274,284 | 0 |
| Phase 2: Single agent rucaparib in metastatic/locally advanced pancreatic cancer | Clovis Oncology, Inc. | $243,686 | 0 |
| A Phase 3 Multicenter, Open-label, Randomized Study of Rucaparib versus Weekly Paclitaxel in Patients with BRCA-mutant or BRCA-like Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Clovis Oncology, Inc. | $130,548 | 0 |
| Phase 1b: Irinotecan + rucaparib basket study in any solid tumor cancers with BRCA1 or BRCA2 mutations | Clovis Oncology, Inc. | $114,696 | 0 |
| A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | Clovis Oncology, Inc. | $73,434 | 0 |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | Clovis Oncology, Inc. | $42,895 | 0 |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | Clovis Oncology, Inc. | $16,425 | 0 |
Top Doctors Receiving Payments for RUBRACA — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Urology | Troy, MI | $2,728 | 8 |
| , MD | Urology | Evergreen Park, IL | $2,556 | 5 |
| , MD | Medical Oncology | Evanston, IL | $2,539 | 5 |
| , MD | Urology | Chicago, IL | $2,509 | 4 |
| , M.D | Urology | Melrose Park, IL | $2,437 | 3 |
| , MD | Urology | Wichita, KS | $2,363 | 4 |
| , M.D | Urology | Rosemont, PA | $2,353 | 7 |
| , MD | Urology | Jeffersonville, IN | $2,250 | 4 |
| , DO | Urology | Sewell, NJ | $2,250 | 4 |
| , M.D | Urology | Lancaster, PA | $2,159 | 4 |
| , M.D | Urology | Virginia Beach, VA | $1,918 | 5 |
| , MD | Urology | Tallahassee, FL | $1,901 | 3 |
| , M.D | Urology | Baltimore, MD | $1,901 | 3 |
| , MD | Urology | San Bernardino, CA | $1,137 | 1 |
Ad
Manufacturing Companies
- Clovis Oncology, Inc. $4.8M
Product Information
- Type Drug
- Total Payments $4.8M
- Total Doctors 38
- Transactions 2,019
About RUBRACA
RUBRACA is a drug associated with $4.8M in payments to 38 healthcare providers, recorded across 2,019 transactions in the CMS Open Payments database. The primary manufacturer is Clovis Oncology, Inc..
Payment data is available from 2017 to 2022. In 2022, $2.2M was paid across 297 transactions to 1 doctors.
The most common payment nature for RUBRACA is "Unspecified" ($4.7M, 97.3% of total).
RUBRACA is associated with 13 research studies, including "A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3)" ($808,069).